SAMATATUG ZOVODOTIN
UNII LY8P78RG35

Substance Identification & Data

This profile provides standardized clinical and technical data for Samatatug Zovodotin, uniquely identified by the FDA Unique Ingredient Identifier (UNII) LY8P78RG35.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

LY8P78RG35

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

SAMATATUG ZOVODOTIN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C181018

National Cancer Institute reference terminology for clinical and research data.

INN ID

12922

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Samatatug Zovodotin

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Samatatug Zovodotin. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Samatatug Zovodotin

Common Names & Synonyms

Immunoglobulin G1 [de-C-terminal-lysine], anti-(human blood-coagulation factor III) (human monoclonal XB002 γ1-chain), disulfide with human monoclonal XB002 κ-chain, dimer, reduced, tetrakis(thioether) with N-[3-[2-[2-[2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)ethoxy]ethoxy]ethoxy]-1-oxopropyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[[[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[(N,N-dimethyl-L-valyl-L-valyl)methylamino]-3-methoxy-5-methyl-1-oxoheptyl]-2-pyrrolidinyl]-3-methoxy-2-methyl-1-oxopropyl]amino]sulfonyl]phenyl]-L-ornithinamide

a cleavable linker to a derivative of auristatin; H-gamma1 heavy chain Homo sapiens (1-452) [VH (Homo sapiens IGHV1-18*01 (94.9%) -(IGHD) -IGHJ3*01 (92.3%) M123>T (118), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123) -Homo sapiens IGHG1*03 (100%), G1m3, nG1m1 CH1 R120, CH3 E12, M14 (CH1 R120 (220) (124-221), hinge 1-15 (222-236), CH2 (237-346), CH3 E12 (362), M14 (364) (347-451), CHS K2>del (452)) (124-452)], (226-215')-disulfide with L-kappa light chain Homo sapiens (1'-215') [V-KAPPA (Homo sapiens IGKV1-5*03 (91.4%) -IGKJ4*01 (91.7%), CDR-IMGT [6.3.10] (27'-32'.50'-52'.89'-98')) (1'-108') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (154'), V101 (192') (109'-215')]; dimer (232-232'':235-235'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-DG44, co-expressing the enzyme dihydrofolate reductase (DHFR), glycoform alfa; substituted at the sulfur atoms of four L-cysteinyl residues on an average among 226, 232, 235, 215', 226'', 232'', 235'' and 215''' with radical group (3RS)-1-[(6S,9S)-1-amino-6-{[4-({N,N-dimethyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(2R,3R)-3-methoxy-2-methyl-3-[(2S)-pyrrolidin-2-yl]propanoyl}sulfamoyl)phenyl]carbamoyl}-1,8,11-trioxo-9-(propan-2-yl)-14,17,20-trioxa-2,7,10-triazadocosan-22-yl]-2,5-dioxopyrrolidin-3-yl (zovodotin)

immunoglobulin G1-kappa, anti-[Homo sapiens F3 (coagulation factor III (thromboplastin, tissue factor), CD142)], Homo sapiens monoclonal antibody, conjugated on an average of 4 cysteinyl residues via a cleavable linker to a derivative of auristatin

samatatug zovodotin [INN]

External Clinical & Regulatory Resources

Previous UNIILY8KTQ8XSR

Next UNIILY92391J8Y